Pulmonary hypertension: Diagnostics and therapeutics

Mayo Clinic Proceedings

Volumn 75, Issue 6, 2000, Pages 625-630

  Krowka, Michael J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; PROSTACYCLIN;

ANTICOAGULATION; DIAGNOSTIC TEST; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFECT; ELECTROCARDIOGRAPHY; HEART CATHETERIZATION; HEMODYNAMICS; HUMAN; PULMONARY HYPERTENSION; REVIEW; SCREENING; THORAX RADIOGRAPHY;

EID: 0034091316     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/75.6.625     Document Type: Review

References (17)

1. McGoon MD, Fuster V, Freeman WK, Edwards WD, Scott JP. Pulmonary hypertension. In: Giuliani ER, Gersh BJ, McGoon MD, Hayes DL, Schaff HV, eds. Mayo Clinic Practice of Cardiology. 3rd ed. St Louis, Mo: Mosby; 1996:1815-1836.
2. Peacock AJ. Primary pulmonary hypertension. Thorax. 1999;54: 1107-1118.
3. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med. 1987; 107:216-223.
4. Kim WR, Krowka MJ, Plevak DJ, et al. Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl. In press.
5. Mayo Pulmonary Hypertension Clinic. Available at: www.mayo.edu/cv/wwwpg_cv/pul_cln/pulclnhp.htm. Accessed May 5, 2000.
6. Murin S, Marelich GP, Arroliga AC, Matthay RA. Hereditary thrombophilia and venous thromboembolism. Am J Respir Crit Care Med. 1998;158:1369-1373.
7. Krowka MJ. Hepatopulmonary syndrome versus portopulmonary hypertension: distinctions and dilemmas [editorial]. Hepatology. 1997;25:1282-1284.
8. Abenhaim L, Moride Y, Brenot F, et al, International Primary Pulmonary Hypertension Study Group. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med. 1996;335:609-616.
9. Cool CD, Stewart JS, Werahera P, et al. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hyperten sion using cell-specific markers: evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol. 1999;155:411-419.
10. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984;70:580-587.
11. Rich S, Seidlitz M, Dodin E, et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest. 1998;114:787-792.
12. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med. 1998;338:273-277.
13. Nagaya N, Uematsu M, Okano Y, et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol. 1999;34:1188-1192.
14. Archibald CJ, Auger WR, Fedullo PF, et al. Long-term outcome after pulmonary thromboendarterectomy. Am J Respir Crit Care Med. 1999;160:523-528.
15. Kerstein D, Levy PS, Hsu DT, Hordof AJ, Gersony WM, Barst RJ. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation. 1995;91:2028-2035.
16. United Network for Organ Sharing (UNOS) 1999 Annual Report. Available at: www.unos.org./frame_default.asp?category=anrpt.Accessed on May 5, 2000.
17. Whyte RI, Robbins RC, Altinger J, et al. Heart-lung transplantation for primary pulmonary hypertension. Ann Thorac Surg. 1999;67: 937-941.